# nature portfolio

Corresponding author(s):	Jing Yan
Last updated by author(s):	Dec 4, 2024

## **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

< ∙	tっ	1		۲ı	~
. )	ıd	ш	1.5	ıI	CS

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	The exact sample size $(n)$ for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
$\boxtimes$	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
$\boxtimes$	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
$\times$	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
$\boxtimes$	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
$\boxtimes$	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i> ), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

#### Software and code

Policy information about availability of computer code

Data collection

Nikon NIS-Elements AR (version 5.21.02) was used for image acquisition and rendering.

Data analysis

Images were analyzed using custom written Matlab codes (version R2021a); they are not central to the conclusion of the paper. Simulation was performed with LAMMPS (version 30 Jul 2016) and key simulation codes are deposited in Github and a statement is included in manuscript regarding how to access the codes. All snapshots of CGMD simulations are rendered using VMD68 version 1.9.3.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

#### Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

A data availability statement is included in the manuscript: "Source data are provided as a Source Data file with this paper. Raw microscopy data generated in this study have been deposited in Dryad under accession code https://doi.org/10.5061/dryad.zcrjdfnph."

Research inv	volving hu	man participants, their data, or biological material		
,		vith <u>human participants or human data</u> . See also policy information about <u>sex, gender (identity/presentation),</u> thnicity and racism.		
Reporting on sex	and gender	Not relevant for this study.		
Reporting on rac other socially rela groupings		Not relevant for this study.		
Population characteristics		Not relevant for this study.		
Recruitment		Not relevant for this study.		
Ethics oversight		Not relevant for this study.		
Note that full informa	ation on the appr	oval of the study protocol must also be provided in the manuscript.		
Field and	oific ro	norting		
Field-spe		. 9		
Please select the o	ne below that is	s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
🔀 Life sciences	В	ehavioural & social sciences		
For a reference copy of	the document with	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
Life scier	nces stu	udy design		
All studies must dis	sclose on these	points even when the disclosure is negative.		
Sample size	least three inde	le-size calculations were performed. The sample size was chosen according to the convention in the field. Data were taken from at see independent experiments. For those that were imaged over time, repeated measurements were made on independent biofilms to he quantitative behaviour.		
Data exclusions	No data were e	were excluded from the analyses.		
Replication	Data was generated from repeated experiments. Each experiment was successful and exhibited the same reproducible behavior. The number of repeats was listed in each figure legend.			
Randomization	This is not relev	his is not relevant for the current study, according to the convention of biofilm research.		
Blinding	Blinding was not relevant in this study. Identical computational analysis tools were applied to all samples and were agnostic to the exact experimental conditions.			
We require informati	on from authors	Decific materials, systems and methods about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & ex		<del></del>		
Antibodies ChIP-seq				
	nd other organism	I		
Clinical data				
	esearch of concer	n		
Plants				

### Plants

Seed stocks	N/A
Novel plant genotypes	N/A
Authentication	N/A